{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:52:38Z","timestamp":1761562358610,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.cgh.2018.03.025","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T02:38:12Z","timestamp":1522118292000},"page":"1434-1441.e21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost Effectiveness of Biomarker Tests for Irritable Bowel Syndrome With Diarrhea: A Framework for Payers"],"prefix":"10.1016","volume":"16","author":[{"given":"Christopher V.","family":"Almario","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin D.","family":"Noah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alma","family":"Jusufagic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8843-6447","authenticated-orcid":false,"given":"Daniel","family":"Lew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brennan M.R.","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2018.03.025_bib1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.03.025_bib2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.2015.0954","article-title":"Irritable bowel syndrome: a clinical review","volume":"313","author":"Chey","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2018.03.025_bib3","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl","key":"10.1016\/j.cgh.2018.03.025_bib4","first-page":"3","article-title":"The clinical and economic burden of irritable bowel syndrome","volume":"31","author":"Lembo","year":"2007","journal-title":"Pract Gastroenterol"},{"key":"10.1016\/j.cgh.2018.03.025_bib5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/apt.13351","article-title":"Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders","volume":"42","author":"Camilleri","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.03.025_bib6","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.molmed.2009.08.001","article-title":"Irritable bowel syndrome: towards biomarker identification","volume":"15","author":"Clarke","year":"2009","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.cgh.2018.03.025_bib7","doi-asserted-by":"crossref","first-page":"e0126438","DOI":"10.1371\/journal.pone.0126438","article-title":"Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects","volume":"10","author":"Pimentel","year":"2015","journal-title":"PloS One"},{"year":"2016","author":"Drossman","series-title":"Rome IV multidimensional clinical profile for functional gastrointestinal disorders","key":"10.1016\/j.cgh.2018.03.025_bib8"},{"key":"10.1016\/j.cgh.2018.03.025_bib9","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/ajg.2010.47","article-title":"Is irritable bowel syndrome a diagnosis of exclusion? a survey of primary care providers, gastroenterologists, and IBS experts","volume":"105","author":"Spiegel","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.03.025_bib10","first-page":"153","article-title":"\"Red flag\" evaluation yield in irritable bowel syndrome","volume":"21","author":"Black","year":"2012","journal-title":"J\u00a0Gastrointest Liver Dis"},{"key":"10.1016\/j.cgh.2018.03.025_bib11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2006.04.029","article-title":"Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis","volume":"131","author":"Vakil","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.03.025_bib12","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/gut.2003.021857","article-title":"Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia","volume":"53","author":"Hammer","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2018.03.025_bib13","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/ajg.2017.154","article-title":"ACG and CAG clinical guideline: management of dyspepsia","volume":"112","author":"Moayyedi","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.03.025_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/ajg.2016.466","article-title":"Screening for celiac disease in irritable bowel syndrome: an updated systematic review and meta-analysis","volume":"112","author":"Irvine","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.03.025_bib15","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.cgh.2012.12.038","article-title":"A\u00a0positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome","volume":"11","author":"Begtrup","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.03.025_bib16","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1053\/j.gastro.2009.08.047","article-title":"Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report","volume":"137","author":"Spiegel","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.03.025_bib17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2036.2010.04328.x","article-title":"Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome","volume":"32","author":"Ford","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.03.025_bib18","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness: the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"unstructured":"The Institute for Clinical Research and Health Policy Studies. Cost-Effectiveness Analysis Registry. 2017. Available from: https:\/\/research.tufts-nemc.org\/cear4\/Home.aspx. Accessed May 1,\u00a02017.","key":"10.1016\/j.cgh.2018.03.025_bib19"},{"key":"10.1016\/j.cgh.2018.03.025_bib20","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1038\/ajg.2009.232","article-title":"Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort","volume":"104","author":"Spiegel","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.03.025_bib21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0016-5085(95)90373-9","article-title":"Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time","volume":"109","author":"Agreus","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.03.025_bib22","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1365-2036.2004.01938.x","article-title":"Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States population","volume":"19","author":"Locke","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.03.025_bib23","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cgh.2006.05.019","article-title":"The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage","volume":"4","author":"Spiegel","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.03.025_bib24","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1365-2036.2007.03464.x","article-title":"The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy: a decision analysis","volume":"26","author":"Huang","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.03.025_bib25","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1007\/s10620-012-2289-y","article-title":"Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey","volume":"57","author":"Gunnarsson","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2018.03.025_bib26","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1053\/j.gastro.2008.09.012","article-title":"Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults","volume":"135","author":"Kappelman","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.03.025_bib27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/archinternmed.2009.22","article-title":"Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis","volume":"169","author":"Ford","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cgh.2018.03.025_bib28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/MCG.0000000000000582","article-title":"The severity of symptoms related to irritable bowel syndrome is a risk factor for\u00a0the misclassification of significant organic disease","volume":"51","author":"Carter","year":"2017","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2018.03.025_bib29","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3109\/00365521.2015.1007079","article-title":"Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey","volume":"50","author":"Patel","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.03.025_bib30","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/apt.13573","article-title":"Systematic review with meta-analysis: diagnostic overlap of microscopic colitis and functional bowel disorders","volume":"43","author":"Guagnozzi","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.03.025_bib31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2169\/internalmedicine.52.9147","article-title":"A\u00a0meta-analysis of the therapeutic effects of amitriptyline for treating irritable bowel syndrome","volume":"52","author":"Chao","year":"2013","journal-title":"Intern Med"},{"key":"10.1016\/j.cgh.2018.03.025_bib32","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3748\/wjg.15.1548","article-title":"Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis","volume":"15","author":"Rahimi","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.03.025_bib33","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1053\/j.gastro.2015.07.054","article-title":"Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial","volume":"149","author":"Bohn","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.03.025_bib34","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/ajg.2016.434","article-title":"A\u00a0randomized controlled trial comparing the low FODMAP diet vs modified NICE guidelines in US adults with IBS-D","volume":"111","author":"Eswaran","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.03.025_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(15)32237-X","article-title":"Mo1292 Low FODMAP diet for irritable bowel syndrome comes of age: a systematic review and meta-analysis","volume":"148","author":"Khan","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2018.03.025_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003460.pub3","article-title":"Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome","author":"Ruepert","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2018.03.025_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2018.03.025_bib38","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2018.03.025_bib39","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2036.2010.04328.x","article-title":"Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome","volume":"32","author":"Ford","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.03.025_bib40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1524-4733.2007.00179.x","article-title":"Economic evaluation of tegaserod vs placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study","volume":"10","author":"Bracco","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.cgh.2018.03.025_bib41","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1365-2036.2010.04242.x","article-title":"Cost effectiveness of mass screening for coeliac disease is determined by time-delay to diagnosis and quality of life on a gluten-free diet","volume":"31","author":"Hershcovici","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.03.025_bib42","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1046\/j.1365-2036.2003.01545.x","article-title":"Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications","volume":"17","author":"Ladabaum","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.03.025_bib43","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1365-2036.2004.01958.x","article-title":"Serological testing for coeliac disease in\u00a0patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis","volume":"19","author":"Mein","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.03.025_bib44","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s10198-012-0441-4","article-title":"Targeted screening for coeliac disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information","volume":"14","author":"Mohseninejad","year":"2013","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.cgh.2018.03.025_bib45","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1038\/ajg.2009.232","article-title":"Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort","volume":"104","author":"Spiegel","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.03.025_bib46","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1471-230X-12-149","article-title":"Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care","volume":"12","author":"Stamuli","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.cgh.2018.03.025_bib47","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1471-230X-12-104","article-title":"The impact of irritable bowel syndrome on health-related quality of life: a Singapore perspective","volume":"12","author":"Wang","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.cgh.2018.03.025_bib48","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4321\/S1130-01082005001100004","article-title":"Perceived health status in celiac disease","volume":"97","author":"Casellas","year":"2005","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.cgh.2018.03.025_bib49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3748\/wjg.14.46","article-title":"Factors that impact health-related quality of life in adults with celiac disease: a multicenter study","volume":"14","author":"Casellas","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.03.025_bib50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1472-6963-10-105","article-title":"Impact of symptoms on quality of life before and after diagnosis of coeliac disease: results from a UK population survey","volume":"10","author":"Gray","year":"2010","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.cgh.2018.03.025_bib51","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-230X-11-118","article-title":"Delay to celiac disease diagnosis and its implications for health-related quality of life","volume":"11","author":"Norstrom","year":"2011","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.cgh.2018.03.025_bib52","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.cgh.2006.05.003","article-title":"Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis?","volume":"4","author":"Arseneau","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.03.025_bib53","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.MIB.0000159661.55028.56","article-title":"Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study","volume":"11","author":"Casellas","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.03.025_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13554-012-0007-0","article-title":"Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis in the Netherlands","volume":"3","author":"Chaudhary","year":"2013","journal-title":"Biol Ther"},{"key":"10.1016\/j.cgh.2018.03.025_bib55","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/ibd.21904","article-title":"Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease","volume":"18","author":"Doherty","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.03.025_bib56","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cgh.2009.10.032","article-title":"Cost effectiveness\u00a0of alternative imaging strategies for the diagnosis\u00a0of small-bowel Crohn's disease","volume":"8","author":"Levesque","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2018.03.025_bib57","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2036.2008.03709.x","article-title":"Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease\u2014modelling outcomes in active luminal and fistulizing disease in adults","volume":"28","author":"Lindsay","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.03.025_bib58","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10198-012-0430-7","article-title":"Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease","volume":"14","author":"Marchetti","year":"2013","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.cgh.2018.03.025_bib59","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.crohns.2009.11.010","article-title":"A\u00a0comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis","volume":"4","author":"Poole","year":"2010","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2018.03.025_bib60","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s10620-013-2820-9","article-title":"Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-alpha inhibitors in Crohn's disease","volume":"59","author":"van der Have","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2018.03.025_bib61","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.cgh.2012.12.035","article-title":"A\u00a0test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab","volume":"11","author":"Velayos","year":"2013","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356518302817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356518302817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:25:16Z","timestamp":1761542716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356518302817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1542356518302817"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2018.03.025","relation":{},"ISSN":["1542-3565"],"issn-type":[{"type":"print","value":"1542-3565"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost Effectiveness of Biomarker Tests for Irritable Bowel Syndrome With Diarrhea: A Framework for Payers","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2018.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the AGA Institute","name":"copyright","label":"Copyright"}]}}